$INNV PR $0.253 mutiple support 'bottom' Rentr
Post# of 405
Posted On: 12/02/2016 5:11:21 PM
Re: Honeycomb777 #122
$INNV PR $0.253
mutiple support 'bottom'
Rentry last week
$0.2549
Flag support
multi-bagger corrected
OTC
100% Sell
Barchart
Might be 1st time I've recommended a 100% Sell
Last ten trades
Website
12/1/16
Innovus Pharma Launches its Clinically Proven UriVarx™ Product
for Bladder Health Through its Beyond Human® Sales and Marketing
Platform in the United States
11/29/16
Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
Nov 21, 2016 Innovus Pharma Launches Zestra® Multi-Dose Form for Female Sexual Arousal in the U.S. Press Release
Nov 18, 2016 Innovus Pharma (INNV) Continues to Execute with Record Q3 '16 Revenue -- SECFilings.com Press Release
Nov 10, 2016 Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016, Increasing 947% to $1.9 Million, and Record Nine Months Ended September 2016 Revenues, Increasing 463% to $3.1 Million Press Release
Nov 8, 2016 Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon Press Release
Nov 7, 2016 Innovus Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Thursday, November 10, 2016 Press Release
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
mutiple support 'bottom'
Rentry last week
$0.2549
Flag support
multi-bagger corrected
OTC
100% Sell
Barchart
Might be 1st time I've recommended a 100% Sell
Last ten trades
Website
12/1/16
Innovus Pharma Launches its Clinically Proven UriVarx™ Product
for Bladder Health Through its Beyond Human® Sales and Marketing
Platform in the United States
11/29/16
Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
Nov 21, 2016 Innovus Pharma Launches Zestra® Multi-Dose Form for Female Sexual Arousal in the U.S. Press Release
Nov 18, 2016 Innovus Pharma (INNV) Continues to Execute with Record Q3 '16 Revenue -- SECFilings.com Press Release
Nov 10, 2016 Innovus Pharma Reports Record Quarterly Revenues for the Third Quarter of 2016, Increasing 947% to $1.9 Million, and Record Nine Months Ended September 2016 Revenues, Increasing 463% to $3.1 Million Press Release
Nov 8, 2016 Innovus Pharma Signs Exclusive License and Distribution Agreement with Elis Pharmaceuticals for Zestra® in Lebanon Press Release
Nov 7, 2016 Innovus Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Thursday, November 10, 2016 Press Release
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
(0)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼